Division: Pharmacy Policy	Subject: Prior Authorization Criteria
Original Development Date: Original Effective Date: Revision Date:	December 22, 2017

YESCARTA™ (axicabtagene ciloleucel suspension)

LENGTH OF AUTHORIZATION: Date of service

ADMINISTRATION: Hospital inpatient setting

REVIEW CRITERIA:

- Patient must be 18 years of age or older.
- Must have relapsed or refractory non-Hodgkin lymphoma.
- Must have tried and failed at least two lines of systemic therapy.

DOSING:

YESCARTA™ comprises a suspension of 2×10^6 CAR-positive viable T cells per kg body weight, with a maximum of 2×10^8 CAR-positive viable T cells in approximately 68 ml.

* Because of the risk of Cytokine Release Syndrome and neurological toxicities, YESCARTA™ is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the YESCARTA™ REMS. Further information is available at www.YescartaREMS.com or 1-844-454-KITE (5483).